China Medical System Tightens Nomination Committee Governance Rules

China Medical System Holdings ( (HK:0867) ) has shared an update.

China Medical System Holdings has updated the terms of reference for its nomination committee, which oversees the selection, appointment and reappointment of directors within the group. The revision, effective 16 March 2026, refines the committee’s composition, meeting procedures and authority in line with evolving listing rules and regulatory expectations.

The new terms require the nomination committee to comprise at least three directors, with a majority being independent non-executive directors and at least one member of a different gender, reinforcing diversity and independence in board oversight. The document also formalises quorum rules, meeting frequency, information rights and the committee’s ability to seek external professional advice, underscoring a stronger corporate governance framework for the company and its stakeholders.

The most recent analyst rating on (HK:0867) stock is a Buy with a HK$17.00 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.

More about China Medical System Holdings

China Medical System Holdings is a pharmaceutical group based in China, operating through its subsidiaries and listed on the Hong Kong Stock Exchange. The company is governed by a board of directors that includes executive and independent non-executive members, and it maintains board committees to oversee key aspects of corporate governance.

YTD Price Performance: -1.47%

Average Trading Volume: 3,920,495

Technical Sentiment Signal: Buy

Current Market Cap: HK$31.01B

For an in-depth examination of 0867 stock, go to TipRanks’ Overview page.